Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming

Blood

Volumn 114, Issue 3, 2009, Pages 693-701

  Highfill, Steven L ^a   Kelly, Ryan M ^a   O'Shaughnessy, Matthew J ^a   Zhou, Qing ^a   Xia, Lily ^a   Panoskaltsis Mortari, Angela ^a   Taylor, Patricia A ^a   Tolar, Jakub ^a   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; MULTIPOTENT STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SPLEEN; T LYMPHOCYTE; TISSUE INJURY; ADULT STEM CELL; ANIMAL; ANTIGEN PRESENTATION; BIOSYNTHESIS; CELL MOTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METHODOLOGY; TRANSPLANTATION;

ADULT STEM CELLS; ANIMALS; ANTIGEN PRESENTATION; BONE MARROW TRANSPLANTATION; CELL MOVEMENT; DINOPROSTONE; GRAFT VS HOST DISEASE; LYMPHOCYTE ACTIVATION; MICE; MULTIPOTENT STEM CELLS; SPLEEN;

EID: 70149119503     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-213850     Document Type: Article

References (47)

1. Fibbe WE, Nauta AJ, Roelofs H. Modulation of immune responses by mesenchymal stem cells. Ann N Y Acad Sci. 2007;1106:272-278. (Pubitemid 47443061)
2. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol. 2006;36:2566-2573. (Pubitemid 44608440)
3. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res. 2005;305:33-41. (Pubitemid 40380651)
4. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843. (Pubitemid 34534559)
5. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619-4621. (Pubitemid 38745993)
6. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2007;109:228-234. (Pubitemid 46053063)
7. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815-1822. (Pubitemid 40223708)
8. Di Ianni M, Del Papa B, De Ioanni M, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol. 2008;36:309-318. (Pubitemid 351221170)
9. Augello A, Tasso R, Negrini SM, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol. 2005;35:1482-1490. (Pubitemid 40691430)
10. Yañez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006;24:2582-2591. (Pubitemid 44674320)
11. Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21:1992-1999. (Pubitemid 47299975)
12. Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol. 2006;176:7761-7767. (Pubitemid 43849077)
13. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41-49. (Pubitemid 34742565)
14. Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol. 2002;30:896-904. (Pubitemid 34845893)
15. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem. 1997;64:278-294. (Pubitemid 27065442)
16. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000;28:875-884.
17. Tolar J, Osborn M, Bell S, et al. Real-time in vivo imaging of stem cells following transgenesis by transposition. Mol Ther. 2005;12:42-48. (Pubitemid 40862355)
18. Gudmundsdottir H, Wells AD, Turka LA. Dynamics and requirements of T-cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J Immunol. 1999;162:5212-5223. (Pubitemid 29307126)
19. Song HK, Noorchashm H, Lieu YK, et al. In vivo MLR: a novel method for the study of alloimmune responses. Transplant Proc. 1999;31:834-835. (Pubitemid 29127699)
20. Blazar BR, Taylor PA, McElmurry R, et al. Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via in utero or postnatal transfer. Blood. 1998;92:3949-3959. (Pubitemid 28525222)
21. Breyer A, Estharabadi N, Oki M, et al. Multipotent adult progenitor cell isolation and culture procedures. Exp Hematol. 2006;34:1596-1601. (Pubitemid 44548123)
22. Tolar J, O'Shaughnessy MJ, Panoskaltsis-Mortari A, et al. Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. Blood. 2006;107:4182-4188. (Pubitemid 43726831)
23. + regulatory T-cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007;92:881-888.
24. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T-cells. J Immunol. 2008;181:3933-3946.
25. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000;106:1331-1339.
26. 2 inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells. J Immunol. 2002;168:4446-4454.
27. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 2002;23:144-150.
28. Ruggeri P, Nicocia G, Venza I, Venza M, Valenti A, Teti D. Polyamine metabolism in prostaglandin E2-treated human T lymphocytes. Immunopharmacol Immunotoxicol. 2000;22:117-129. (Pubitemid 30161263)
29. Brown DM, Warner GL, Ales-Martinez JE, Scott DW, Phipps RP. Prostaglandin E2 induces apoptosis in immature normal and malignant B lymphocytes. Clin Immunol Immunopathol. 1992;63:221-229.
30. Ikegami R, Sugimoto Y, Segi E, et al. The expression of prostaglandin E receptors EP2 and EP4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages. J Immunol. 2001;166:4689-4696. (Pubitemid 32233756)
31. 2 that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol. 2001;209:19-28.
32. 2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood. 2009;113:2451-2460.
33. Li H, Guo Z, Jiang X, Zhu H, Li X, Mao N. Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells. 2008;26:2531-2541.
34. Fitzpatrick FA, Aguirre R, Pike JE, Lincoln FH. The stability of 13,14-dihydro-15 keto-PGE2. Prostaglandins. 1980;19:917-931.
35. Pabst R, Westermann J. The role of the spleen in lymphocyte migration. Scanning Microsc. 1991;5:1075-1079; discussion 1079-1080.
36. Anderson BE, Taylor PA, McNiff JM, et al. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T-cells. Blood. 2008;111:5242-5251.
37. Beilhack A, Schulz S, Baker J, et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood. 2008;111:2919-2928.
38. Clouthier SG, Ferrara JL, Teshima T. Graft-versus-host disease in the absence of the spleen after allogeneic bone marrow transplantation. Transplantation. 2002;73:1679-1681.
39. + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004;104:3804-3812.
40. + regulatory T-cells protects from lethal acute GVHD. Blood. 2005;105:2220-2226.
41. + regulatory T-cells during acute graft-versus-host disease. Blood. 2005;106:3300-3307.
42. Zhang N, Schröppel B, Lal G, et al. Regulatory T-cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity. 2009;30:458-469.
43. Aranguren XL, McCue JD, Hendrickx B, et al. Multipotent adult progenitor cells sustain function of ischemic limbs in mice. J Clin Invest. 2008;118:505-514.
44. Pelacho B, Nakamura Y, Zhang J, et al. Multipotent adult progenitor cell transplantation increases vascularity and improves left ventricular function after myocardial infarction. J Tissue Eng Regen Med. 2007;1:51-59.
45. Tolar J, Wang X, Braunlin E, et al. The host immune response is essential for the beneficial effect of adult stem cells after myocardial ischemia. Exp Hematol. 2007;35:682-690.
46. Kovacsovics-Bankowski M, Streeter PR, Mauch KA, et al. Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol. 2009;255:55-60.
47. Ghansah T, Paraiso KH, Highfill S, et al. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T-cell responses. J Immunol. 2004;173:7324-7330.